Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment
Inhaled corticosteroids (ICS) are the core component of asthma treatment and the only maintenance therapy known to prevent asthma death. There is currently no evidence that biologics prevent asthma death in people with asthma, and as such, biologics cannot be recommended as an alternative to ICS the...
Main Authors: | Anna C. Murphy, Claire Boddy, Peter Bradding |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2021-06-01
|
Series: | Breathe |
Online Access: | http://breathe.ersjournals.com/content/17/2/210024.full |
Similar Items
-
Con: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment
by: Ireti Adejumo, et al.
Published: (2021-06-01) -
Cut-Point for Satisfactory Adherence of the Dietary Sodium Restriction Questionnaire for Patients with Heart Failure
by: Karina Sanches Machado d’Almeida, et al. -
Adherence to Treatment in Severe Asthma
by: Adelmir Souza-Machado, MD, et al.
Published: (2010-01-01) -
Should lung biopsies be performed in patients with severe asthma?
by: Daniel Doberer, et al.
Published: (2015-09-01) -
Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence
by: Kevin R Murphy, et al.
Published: (2009-07-01)